PL1866650T3 - Neurodegeneracyjne markery depresji - Google Patents

Neurodegeneracyjne markery depresji

Info

Publication number
PL1866650T3
PL1866650T3 PL06723873T PL06723873T PL1866650T3 PL 1866650 T3 PL1866650 T3 PL 1866650T3 PL 06723873 T PL06723873 T PL 06723873T PL 06723873 T PL06723873 T PL 06723873T PL 1866650 T3 PL1866650 T3 PL 1866650T3
Authority
PL
Poland
Prior art keywords
depression
markers
disease
values
alzheimer
Prior art date
Application number
PL06723873T
Other languages
English (en)
Inventor
Aye Mu Myint
Manfred Schawaller
Robert Verkerk
Markus J Schwarz
NORBERT MüLLER
Original Assignee
Verstappen Leopold
Univ Of Maastricht
Univ Of Antwerp
Klinik Und Poliklinik Fuer Psychiatrie Und Psychotherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verstappen Leopold, Univ Of Maastricht, Univ Of Antwerp, Klinik Und Poliklinik Fuer Psychiatrie Und Psychotherapie filed Critical Verstappen Leopold
Publication of PL1866650T3 publication Critical patent/PL1866650T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Mushroom Cultivation (AREA)
  • Input From Keyboards Or The Like (AREA)
PL06723873T 2005-04-06 2006-03-30 Neurodegeneracyjne markery depresji PL1866650T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05007558 2005-04-06
PCT/EP2006/002907 WO2006105907A1 (en) 2005-04-06 2006-03-30 Neurodegenerative markers for psychiatric conditions
EP06723873A EP1866650B1 (en) 2005-04-06 2006-03-30 Neurodegenerative markers for depression.

Publications (1)

Publication Number Publication Date
PL1866650T3 true PL1866650T3 (pl) 2011-04-29

Family

ID=36293430

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09013088T PL2146209T3 (pl) 2005-04-06 2006-03-30 Neurodegeneratywne markery choroby Alzheimera
PL06723873T PL1866650T3 (pl) 2005-04-06 2006-03-30 Neurodegeneracyjne markery depresji

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09013088T PL2146209T3 (pl) 2005-04-06 2006-03-30 Neurodegeneratywne markery choroby Alzheimera

Country Status (13)

Country Link
US (2) US20080131921A1 (pl)
EP (2) EP2146209B1 (pl)
JP (1) JP4958893B2 (pl)
AT (2) ATE468537T1 (pl)
CY (1) CY1110116T1 (pl)
DE (1) DE602006014379D1 (pl)
DK (2) DK1866650T3 (pl)
ES (2) ES2346467T3 (pl)
NO (2) NO20075671L (pl)
PL (2) PL2146209T3 (pl)
PT (2) PT1866650E (pl)
SI (1) SI1866650T1 (pl)
WO (1) WO2006105907A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2053405A4 (en) * 2006-08-04 2009-11-11 Ajinomoto Kk METHOD FOR EVALUATING STRESS, STRESS EVALUATION DEVICE, STRESS EVALUATION METHOD, STRESS EVALUATION SYSTEM, STRESS EVALUATION PROGRAM AND RECORDING MEDIUM
AT9843U1 (de) 2007-03-27 2008-04-15 Kepplinger Berthold Dr Messung von biologischen markern
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
JP5410997B2 (ja) * 2008-01-31 2014-02-05 則行 川村 うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
WO2009100243A2 (en) * 2008-02-05 2009-08-13 University Of Miami Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients
EP2466312B1 (en) 2009-08-12 2019-10-16 Human Metabolome Technologies, Inc. Phosphoethanolamine as biomarker of depression
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2013069645A1 (ja) 2011-11-10 2013-05-16 ヒューマン・メタボローム・テクノロジーズ株式会社 エタノールアミンリン酸の測定方法
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
US20150285805A1 (en) 2012-11-05 2015-10-08 Ospedale San Raffaele S.R.L. Biomarkers of multiple myeloma development and progression
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
EP2799878A1 (en) * 2013-05-03 2014-11-05 SALION GmbH In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant using kynurenine as a marker.
US20160003857A1 (en) * 2014-07-02 2016-01-07 Cecil Bennett Methods and systems for detecting polypharmacy
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
WO2017185085A1 (en) * 2016-04-22 2017-10-26 Board Of Regents Of The University Of Nebraska Biomarkers for monitoring immune transformation
EP3413050A1 (en) * 2017-06-08 2018-12-12 SALION GmbH In vitro method for the determination of neurodegenerative diseases
WO2019067660A1 (en) * 2017-09-27 2019-04-04 University of North Carolina Wilmington TOOL FOR DETECTION OF PATHOGENIC AGENTS DERIVED FROM MAN AND HUMAN WASTEWATER
WO2019181830A1 (ja) 2018-03-19 2019-09-26 富士フイルム和光純薬株式会社 精神疾患の判定方法
CA3094504A1 (en) * 2018-03-22 2019-09-26 Japan Medical Device Technology Co., Ltd. Bioabsorbable stent
KR102159344B1 (ko) * 2019-08-05 2020-09-23 한국과학기술연구원 행위 중독의 진단용 조성물, 키트 및 이를 이용한 행위 중독의 진단을 위한 키누레닌의 검출 방법
EP4067903A4 (en) * 2019-11-26 2024-03-06 Kyocera Corporation STRESS MEASUREMENT SYSTEM AND STRESS MEASUREMENT METHOD
JP2023549028A (ja) * 2020-10-06 2023-11-22 学校法人沖縄科学技術大学院大学学園 アルツハイマー病（ａｄ）の診断のための指標を得るための方法
JPWO2024253194A1 (pl) * 2023-06-08 2024-12-12
CN118566488B (zh) * 2024-04-10 2026-02-27 合肥歆智医疗器械有限公司 抑郁症检测用试剂组合、制造方法、检测系统及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194217B1 (en) * 1980-01-14 2001-02-27 Esa, Inc. Method of diagnosing or categorizing disorders from biochemical profiles
JP2000131318A (ja) * 1998-10-22 2000-05-12 Nikken Foods Co Ltd 快・不快ストレス状態解析方法
EP1050758A1 (en) * 1999-05-03 2000-11-08 Evotec BioSystems AG Methods of diagnosing or treating neuropsychiatric diseases on basis of increased cerebrospinal fluid levels of neurotrophin 3
FR2827045B1 (fr) * 2001-07-05 2007-08-10 Univ Pasteur Methodes et compositions pour la selection et le developpement de nouveaux agents pharmacologiques ou de nouveaux medicaments
JP2004198325A (ja) * 2002-12-19 2004-07-15 Oriental Yeast Co Ltd ストレスの測定方法

Also Published As

Publication number Publication date
EP2146209B1 (en) 2011-11-16
ATE534038T1 (de) 2011-12-15
JP4958893B2 (ja) 2012-06-20
EP1866650A1 (en) 2007-12-19
EP2146209A1 (en) 2010-01-20
US20120196300A1 (en) 2012-08-02
NO20075671L (no) 2007-11-06
ES2377704T3 (es) 2012-03-30
WO2006105907A1 (en) 2006-10-12
CY1110116T1 (el) 2015-01-14
NO20120452L (no) 2007-11-06
EP1866650B1 (en) 2010-05-19
DK2146209T3 (da) 2012-02-13
US20080131921A1 (en) 2008-06-05
ATE468537T1 (de) 2010-06-15
PT1866650E (pt) 2010-06-01
ES2346467T3 (es) 2010-10-15
PL2146209T3 (pl) 2012-05-31
DK1866650T3 (da) 2010-09-06
DE602006014379D1 (de) 2010-07-01
HK1137219A1 (en) 2010-07-23
JP2008537111A (ja) 2008-09-11
PT2146209E (pt) 2011-12-30
SI1866650T1 (sl) 2010-12-31

Similar Documents

Publication Publication Date Title
SI1866650T1 (sl) Nevrodegenerativni markerji za depresijo
WO2005047484A3 (en) Biomarkers for alzheimer's disease
PL1945622T3 (pl) Izotopowo znaczone związki benzofuranu jako środki obrazujące białka amyloidogenne
GB0512401D0 (en) Method
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
WO2007106762A3 (en) Alzheimer's disease biomarkers and methods of use
ZA200810528B (en) Procedure and methods for detecting Alzheimer's disease
ZA200800975B (en) Oral, quickly disintegrating film, which cannot be spat out, for an antiemetic or antimigraine agent
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
FR2874675B1 (fr) Frein pour roue avec capteur d'usure
AU2374302A (en) Means for detecting pathological transformation of the app protein and their uses
EP1948831A4 (en) ALZHEIMER ASSOCIATED GENETIC POLYMORPHISMS, DETECTION METHOD AND USE THEREOF
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
EP1855525A4 (en) FISH MODELS ZEBRA OF ALZHEIMER'S DISEASE
FR2890446B1 (fr) Methode de detection d'interaction intracellulaire entre bio-molecules
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo
DE602006016568D1 (de) Vorrichtung zur bestimmung des reifenaufblasdrucks
WO2005116659A3 (en) Compositions and methods relating to alzheimer’s disease
WO2007066129A3 (en) A method of detecting skeletal muscle damage
GB0622194D0 (en) Method for diagnosing or detecting alzheimer's disease
EP1907838A4 (en) FRAGMENT OF THE NEUROSCRETOR PROTEIN VGF AS BIOMARKER FOR MORBUS ALZHEIMER
FR2852096B1 (fr) Instrument indicateur de direction permettant d'indiquer l'heure et la direction de la mecque.
HK1111225A (en) Polypeptide marker for diagnosing alzheimer's disease